Anebulo Pharmaceuticals plans reverse stock split to go private
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq futures fall 1% as Alphabet results intensify AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Oil falls as diplomacy hopes outweigh Middle East escalation fears
- SK Hynix shares surge after Q3 profit beats expectations
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
July 23, 2025 8:00 AM EDTAUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or Anebulo), today announced that a Special Committee of independent directors has recommended, and its Board of Directors (the Board) has approved, as part of a going private transaction, a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500 (the Range), with the exact ratio to be set within the Range without further approval or authorization of the Companys stockholders and... More



